Home › Funds › Lynx1 Capital Management LP › TCRX

Lynx1 Capital Management LP position in TCRX

TScan Therapeutics Inc · Health Care

Lynx1 Capital Management LP reported holding 8,019,148 shares of TCRX (TScan Therapeutics Inc) in its Q2 2026 13F filing — a position valued at US$7.9M, representing 0.91% of its reported portfolio and ranking #7 among its reported holdings. Lynx1 Capital Management LP has disclosed TCRX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)8.02M sh
Reported value held$7.86M
Portfolio Weight0.91%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Lynx1 Capital Management LP's TCRX position evolved

Lynx1 Capital Management LP first disclosed a stake in TCRX in Q3 2023 at 5,224,600 shares (US$13.4M). The position peaked in Q1 2024 at 5,224,600 shares, worth US$41.5M. Across 12 filings, Lynx1 Capital Management LP increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 8 time(s). The most recent filing (Q2 2026) shows 8,019,148 shares valued at US$7.9M. Notable position changes include a 47% increase in Q2 2025 (shares rose 26% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 5.22M $13.37M New
Q4 2023 5.22M $30.46M Hold
Q1 2024 5.22M $41.48M Hold
Q2 2024 5.22M $30.56M Hold
Q3 2024 5.22M $26.02M Hold
Q4 2024 5.36M $16.29M Add
Q1 2025 5.36M $7.39M Hold
Q2 2025 7.86M $11.39M Add
Q3 2025 7.86M $14.30M Hold
Q4 2025 8.02M $8.02M Add
Q1 2026 8.02M $8.10M Hold
Q2 2026 8.02M $7.86M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TCRX and 13F data

TCRX (TScan Therapeutics Inc) is a Health Care company. 23 other funds we track also report a position in TCRX — the largest reported positions include DC Funds, LP (US$617.5M), BVF INC/IL (US$5.5M), Deer Management Co. LLC (US$1.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TCRX

All TCRX fund holders →

FAQ

How long has Lynx1 Capital Management LP held TCRX?

Lynx1 Capital Management LP has disclosed TCRX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Lynx1 Capital Management LP's current position in TCRX?

As of Q2 2026, Lynx1 Capital Management LP holds 8.02M shares of TCRX (TScan Therapeutics Inc), valued at $7.86M, representing 0.91% of its reported portfolio and ranking #7.

Has Lynx1 Capital Management LP been buying or selling TCRX?

In the latest 13F filing (Q2 2026), Lynx1 Capital Management LP held unchanged its position in TCRX. The position peaked in Q1 2024 at 5.22M shares.

Which other funds hold TCRX?

Other major institutional holders of TCRX include DC Funds, LP, BVF INC/IL, Deer Management Co. LLC, among 23 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.